Unusual market activity is often the first sign that big changes are coming to a stock. Professional traders and large ...

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

Wednesday, January 14, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie ...

Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent ...

The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest ...

AbbVie commits to lowering Medicaid drug prices and investing $100 billion in US R&D and capital investments over the next decade. The TrumpRx program will expand direct-to-patient offerings, ...

A veteran FDA regulator who left last month said the firewall between agency political appointees and drug reviewers “has ...

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

AbbVie has also pledged to participate in TrumpRx and offer many of its products, including Humira, on a direct-to-patient ...

Though far from the first large drugmaker to strike a pricing deal with the Trump administration, AbbVie’s new accord is ...

Hold iShares U.S. Healthcare ETF (IYH): top holdings face GLP-1 risks, patent cliffs and high valuations. Read here for an ...

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...